The role of cannabinoids in dermatology

Mounessa, Jessica S.; Siegel, Julia A.; Dunnick, Cory A.; Dellavalle, Robert P.

doi:10.1016/j.jaad.2017.02.056

Cited by 56 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pruritus entails the largest physical and psychological burden for children with EB, and the reported diminished frequency and intensities of pruritus in these cases is notable as the antipruritic effects of CBMs have been postulated in several dermatological conditions …”

Section: Discussionmentioning

confidence: 99%

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Furthermore, cannabinoids may have anti-inflammatory properties via activation of CB1 receptor which has been shown in mouse models to improve epidermal barrier function, decrease Th2-mediated inflammatory response, and suppress mast cells. 27 In a small study of patients treated with hemodialysis for ESKD, topical application of cream with structured physiologic lipids and endogenous cannabinoids applied twice daily for 3 weeks eliminated pruritus in 8 of 21 patients (38%). 15 In our study, only 5 patients had tried cannabis for pruritus and 4 experienced benefit.…”

Section: Discussionmentioning

confidence: 99%

Cannabis Use for Restless Legs Syndrome and Uremic Pruritus in in patients treated with maintenance dialysis: A Survey

Samaha

Kandiah

Zimmerman

2020

Can J Kidney Health Dis

View full text Add to dashboard Cite

Background: Restless legs syndrome (RLS) and uremic pruritus reduce the quality of life in patients with end-stage kidney disease (ESKD) and current treatments are often insufficient. There is an increasing interest in using cannabinoids for symptom management, and preliminary evidence suggests cannabinoids may help alleviate RLS and pruritus. Objectives: (1) To assess the frequency and severity of RLS and pruritus in our ESKD population with the current treatment options, (2) to estimate patient use of cannabinoids for these symptoms, and (3) to determine interest in participating in future trials to treat RLS and/or pruritus. Design: Survey. Patients: Adult prevalent patients with ESKD treated with dialysis at the Ottawa Hospital. Measurements: International RLS Study Group Rating Scale and visual analogue scale for symptom severity of RLS and pruritus, respectively. Methods: Eligible patients with ESKD treated at the Ottawa Hospital were invited to complete a survey to identify symptoms and severity of RLS and pruritus using validated scales, cannabis use for management, and interest in future trials. Basic demographic statistics to describe the study population and results were used. Results: Sixty-nine percent (192 of 277) of eligible patients completed the surveys, 35 declined participation, and 50 surveys were not returned. Eighty-six (45%) and 129 patients (67%) reported symptoms of RLS and pruritus, respectively. Only 18 previously symptomatic patients were relieved with current treatment. Fifteen patients reported cannabis use for symptoms; 9 noted improvement. Most (>2 of 3) symptomatic patients were interested in participating in a future trial. Limitations: Single-center study in a tertiary-care hospital in Canada limiting generalizability. Quoted prevalence of symptoms is dependent on survey return. Conclusions: A large proportion of ESKD patients suffer from RLS and/or pruritus, most of which are not relieved by existing treatments. Few patients reported trying cannabis to decrease their symptoms despite legalization. This study confirms strong patient interest for future trials regarding cannabis for symptom relief. Trial Registration: Not applicable.

show abstract

“…Since CBD is now approved as oral solution in patients 2 years of age and older, it will be interesting to see the first reports showing improvement of acne vulgaris in adolescents. But also other phytocannabinoids and synthetic cannabinoids targeting cannabinoid receptors or interfering with metabolism show potential for the systemic or topical treatment of skin diseases due to their anti‐inflammatory and anti‐proliferative effects not only on sebocytes, but also on keratinocytes …”

Section: Repurposing Of Neuropharmacological Drugs For Inflammatory Smentioning

confidence: 99%

Can we teach old drugs new tricks?—Repurposing of neuropharmacological drugs for inflammatory skin diseases

Abels

Soeberdt

2019

Experimental Dermatology

View full text Add to dashboard Cite

Despite the “hype” for monoclonal antibodies, the so‐called biologics, which added significant value to the therapeutic armamentarium of dermatologists and improved the life of many patients, but may exhibit significant adverse effects, the vast majority of dermatological patients suffering from atopic dermatitis or psoriasis is still treated topically. Thus, there is a huge need for locally applied, locally acting drugs for inflammatory skin diseases with better risk‐benefit profiles compared to topical corticosteroids or calcineurin inhibitors. Drug repositioning is a complex process, but offers advantages, in particular for indications with lower revenues. In this viewpoint, the neuroendocrine system of the skin is described as an attractive drug target because it contributes significantly to neutralizing external noxious agents prior to inducing immune or vascular changes leading to the clinical signs of skin inflammation, for example, itch and erythema. In addition, epidermis and dermis are accessible for topically applied products which may act locally without pharmacodynamically relevant systemic exposure limiting adverse events. Moreover, since numerous drugs have been evaluated for various CNS diseases, some failed and some approved, this resource should be exploited for repurposing as anti‐inflammatory drugs for topical application, for example, cannabidiol, fingolimod or asimadoline. Finally, a screening algorithm is shared which gives direct evidence of links between drug and inflammatory skin diseases.

show abstract

The role of cannabinoids in dermatology

Cited by 56 publications

References 20 publications

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases

Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases

Cannabis Use for Restless Legs Syndrome and Uremic Pruritus in in patients treated with maintenance dialysis: A Survey

Can we teach old drugs new tricks?—Repurposing of neuropharmacological drugs for inflammatory skin diseases

Contact Info

Product

Resources

About